Avisi Technologies Announces Positive 12-Month Clinical Data on VisiPlate Aqueous Shunt

Avisi Technologies announced positive 12-month clinical data on its VisiPlate Aqueous Shunt from the VITA trial during the 2025 AAO Annual Meeting. The study was presented by Jonathan Myers, MD, chief of the glaucoma service at Wills Eye Hospital, Thomas Jefferson University, in Philadelphia.

The VITA Trial, a prospective pilot study designed to assess the safety and efficacy of the device, was conducted at three centers by three implanting surgeons in South Africa. All 15 treated patients were diagnosed with open-angle glaucoma and had no history of filtration surgery. Unilateral implantation of the VisiPlate was performed as an ab externo standalone procedure.

According to the company, at baseline, patients’ mean diurnal IOP was 24.1 ±6.2 mm Hg on 2.0 ±1.5 glaucoma medications, and their baseline visual field mean deviation was -11.7 ±8.6 dB. At 12 months, the mean diurnal IOP was 13.1 ±2.6 mm Hg on 1.3 ±1.5 medications (a change of -42.6% from baseline), and 46.7% of patients had discontinued all glaucoma medications. No serious adverse events were reported, and no patient experienced persistent vision loss.

The VisiPlate is being studied in the United States in the SAPPHIRE trial.